<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=windows-1251">
<title>Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике</title>
<meta name="description" content="Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике">
<meta name="keywords" content="">
<link rel="StyleSheet" type="text/css" href="include/mcl.css">
<style type="text/css">
P	{text-align: justify;}
OL {margin-left: 25px; text-align: justify;}
LI {margin-top: 10px; margin-bottom: 1px; margin-left: 15px;}
</style>
</head>

<body class="main">

<h3>СПИСОК ЛИТЕРАТУРЫ</h3>

<ol>
<a name="161"></a><li value="161">Araujo F.G., Shepard R.M., Remington J.S. <i>In&nbsp;vivo</i> activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against <i>Toxoplasma gondii</i>. Eur. J.&nbsp;Clin. Microbiol. Infect. Dis., 1991, 10: 519-524.</li>
<a name="162"></a><li value="162">Leport C., Vilde J.L., Katlama C., et al. Failure of spiramycin to prevent neurotoxoplasmosis in immunosuppressed patients. JAMA, 1986, 255: 2290.</li>
<a name="163"></a><li value="163">Decazes J.M., Doco-Lecompte T., Modai J. Echec de fortes doses de roxithromycine dans le traitement de la toxoplasmose cerebrale des patients atteints de SIDA. In: Reunion Interdisciplinaire de Chimiotherapie Antiinfectieuse. Paris, 1988: abstr. 202/C12.</li>
<a name="164"></a><li value="164">Leport C., Fernandez-Martin J., Morlat P., et al. Combination of pyrimethamine-clarithromycin for acute therapy of toxoplasmic encephalitis. A pilot study in 13 AIDS patients. In: The 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, 1990: abstr. 1158.</li>
<a name="165"></a><li value="165">Young L.S. Macrolides as antimycobacterial agents. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 121-129.</li>
<a name="166"></a><li value="166">Havlir D.V., Dube M.P., Sattler F.R., et al. Prophylaxis against disseminated <i>Mycobacterium avium</i> complex with weekly azithromycin, daily rifabutin, or both. N.&nbsp;Engl. J.&nbsp;Med., 1996, 335: 392-398.</li>
<a name="167"></a><li value="167">Chang H.R., Pechere J.C. Macrolides in toxoplasmosis. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 131-140.</li>
<a name="168"></a><li value="168">Ji B., Jamet P., Perani E.G., et al. Powerful bactericidal activity of clarithromycin and minocycline against <i>Mycobacterium leprae</i> in the treatment of lepromatous leprosy. J.&nbsp;Infect. Dis., 1993, 168: 188-190. </li>
<a name="169"></a><li value="169">Young L.S. Atypical mycobacteria. In: Textbook of AIDS Medicine. Broder&nbsp;S., Merigan&nbsp;T.C., Bolognesi&nbsp;D. (Eds.). Baltimore, 1993: 283-294.</li>
<a name="170"></a><li value="170">Gorzynski E.A., Gutman S.I., Allen W. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob. Agents Chemother., 1989, 33: 591-592.</li>
<a name="171"></a><li value="171">Luna-Herrera J., Reddy V.M., Gangadharam P.R.J. Synergistic effect of clarithromycin and isoniazid and rifampin against tubercle bacilli. In: The 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, 1994: abstr. E134.</li>
<a name="172"></a><li value="172">Massarotti E.M., Luger S.W., Rahn D.W., et al. Treatment of Lyme disease. Am. J.&nbsp;Med., 1992. 92: 396-403.</li>
<a name="173"></a><li value="173">Strle F., Ruzic E., Cimperman J. Erythema migrans comparison of treatment with azithromycin, doxycycline and phenoximethylpenicillin. J.&nbsp;Antimicrob. Chemother., 1992, 30: 543-550.</li>
<a name="174"></a><li value="174">Freeman E. Periodontal disease. Part III. Chemotherapeutics. Can. Fam. Physician, 1988, 34: 1395-1397.</li>
<a name="175"></a><li value="175">Mills W.H., Thompson G.W., Beagrie G.S. Clinical evaluation of spiramycin and erythromycin in control of periodontal disease. J.&nbsp;Clin. Periodontol., 1979, 6: 308-316.</li>
<a name="176"></a><li value="176">Chin Quee T., AI-Joburi W., Lautar-Lemay C., et al. Comparison
of spiramycin and tetracycline used adjunctively in the treatment of advanced chronic periodontitis. J.&nbsp;Antimicrob. Chemother., 1988, 22 (suppl. B): 171-177.</li>
<a name="177"></a><li value="177">Desnica B., Burek V., Makek N. Azithromycin/ranitidine combined treatment of <i>H.pylori</i> in patients with duodenal ulcer and chronic gastritis - a pilot study. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 5.22.</li>
<a name="178"></a><li value="178">Lamouliatte H., Courrier A., Mion F., et al. Roxithromycin 300&nbsp;mg b.i.d. in association with amoxycillin and lansoprazole on eradication of <i>Helicobacter pylori</i>: results of an open, non-comparative, multicentre study. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996, Roxithromycin Posters: 22.</li>
<a name="179"></a><li value="179">Saikku P., Leinonen M., Mattila K., et al. Serologic evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet ii, 1988: 983-985.</li>
<a name="180"></a><li value="180">Saikku P. <i>Chlamydia pneumoniae</i> and cardiovascular disease. Clin. Microbiol. Infect., 1996, 1 (suppl. 1): S19-22.</li>
<a name="181"></a><li value="181">Gupta S., Leatham E.W., Carrington D., et al. Elevated <i>Chlamydia pneumoniae</i> antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation, 1997, 96; 404-407.</li>
<a name="182"></a><li value="182">Danesh J., Collins R., Peto R. Chronic infections and coronary heart disease: is there a link? Lancet, 1997, 350: 430-436.</li>
<a name="183"></a><li value="183">Gupta S., Leatham E.W., Carrington D., et al. The effect of azithromycin in post myocardial infarction patients with elevated <i>Chlamydia pneumoniae</i> antibody titres. J. Am. Coll. Cardiol., 1997, 29 (suppl. A): 209A.</li>
<a name="184"></a><li value="184">Gurfinkel E., Bozovich G., Daroca A., et al. Randomised trial of roxithromycin in non Q-wave coronary syndromes: ROXIS pilot study. Lancet, 1997, 350: 404-407.</li>
<a name="185"></a><li value="185">Kraft M., Cassell G.H., Aerni M., et al. <i>Mycoplasma pneumoniae</i> as a cofactor in the pathogenesis of chronic asthma. In: European Respiratory Society. Annual Congress. Berlin, 1997; abstr. P0292.</li>
<a name="186"></a><li value="186">Blasi F., Cosentini R., Fagetti L., et al. <i>Chlamydia pneumoniae</i> and sarcoidosis. In: European Respiratory Society. Annual Congress. Berlin, 1997: abstr. P2097.</li>
<a name="187"></a><li value="187">Frangova-Youroukova V., Ivanov S., Popov G. <i>Chlamydia pneumoniae</i> and respiratory tract diseases in Bulgaria. In: European Respiratory Society. Annual Congress. Berlin, 1997: abstr. P2096.</li>
<a name="188"></a><li value="188">Herbaut A.G., Dachy A., Thys J.P. Chemoprophylaxis for bacterial meningitis, Acta Clin. Belg., 1986, 41: 402-410.</li>
<a name="189"></a><li value="189">Prevention of Recurrent Attacks of Rheumatic Fever. Recommendation of AHA Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease of the Council of Cardiovascular Disease in the Young. Circulation, 1988, 78: 1082.</li>
<a name="190"></a><li value="190">Dajani A.S., Taubert K.A., Wilson W., et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Clin. Cardiol., 1997, 277: 1794-1801.</li>
<a name="191"></a><li value="191">Van Scoy R.E., Wilkowske C.J. Prophylactic use of antimicrobial agents in adult patients. Mayo Clin. Proc., 1992, 76: 288-292.</li>
<a name="192"></a><li value="192">Anderson S.L., Berman J., Kuschner R. Prophylaxis of Plasmodium falciparum malaria azithromycin administered to volunteers. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 8.15.</li>
<a name="193"></a><li value="193">. Linares J., Garau J., Dominiquez C., et al. Antibiotic resistance
and serotypes of <i>Streptococcus pneumoniae</i> from patients with community acquired pneumococcal disease. Antimicrob. Agents Chemother., 1983, 23: 545-547.</li>
<a name="194"></a><li value="194">Acar J.F., Buu-Hoi A.Y. Resistance patterns of important gram-positive pathogens. J.&nbsp;Antimicrob. Chemother., 1988, 21 (suppl.&nbsp;C): 41-47.</li>
<a name="195"></a><li value="195">Maruyama S., Yoshioka H., Fujita K., et al. Sensitivity of group A streptococci to antibiotics. Am. J.&nbsp;Dis. Child., 1979, 133: 1143-1145.</li>
<a name="196"></a><li value="196">Stratchounsky L., Krechikova 0., Bolmstrom A., et al. Susceptibility patterns of clinical strains of <i>Streptococcus pyogenes</i> in Russia. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. C-71.</li>
<a name="197"></a><li value="197">Leclerq R., Courvalin P. Intrinsic and unusual resistance to macrolides, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob. Agents Chemother., 1991, 35: 1273-1276.</li>
<a name="198"></a><li value="198">Garrod L.P., Lambert H.P., O'Grady F. Antibiotic and Chemotherapy. 5th ed. Edinburgh, 1981: 183.</li>
<a name="199"></a><li value="199">Mapple P.A.C., Hamilton-Miller J.M.T. Brumfitt W. World-wide antibiotic resistance in methicillin-resistant <i>Staphylococcus aureus</i>. Lancet, 1989, 1: 537-539.</li>
<a name="200"></a><li value="200">Vanhoff R., Gordts B., Dierickx R., et al. Bacteriostatic and bactericidal activities of 24 antimicrobial agents against <i>Campylobacter fetus</i> subsp. <i>jejuni</i>. Antimicrob. Agents Chemother., 1980, 18: 118-121.</li>
<a name="201"></a><li value="201">Brittain D.C. Erythromycin. Med. Clin. North. Am., 1987, 71: 1147.</li>
<a name="202"></a><li value="202">Sabath L.D., Gerstein D.A., Loder P.B., et al. Excretion of erythromycin and its enhanced activity in urine against gram-negative bacilli with alkalinization. Lab. Clin. Med., 1968, 72: 916-923.</li>
<a name="203"></a><li value="203">Jao R.L., Finland M. Susceptibility of Mycoplasma pneumoniae to 21 antibiotics <i>in&nbsp;vitro</i>. Am. J.&nbsp;Med. Sci., 1967, 253: 639-650.</li>
<a name="204"></a><li value="204">Niitu Y., Hasegawa S., Kubota H. <i>In&nbsp;vitro</i> development of resistance to erythromycin, other macrolide antibiotics, and lincomycin in <i>Mycoplasma pneumoniae</i>. Antimicrob. Agents Chemother., 1974, 5: 513-519.</li>
<a name="205"></a><li value="205">Washington J.A., Wilson W.R. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (I). Mayo Clin. Proc., 1985, 60: 189-203.</li>
<a name="206"></a><li value="206">Giving erythromycin by mouth. Drug Therap. Bull., 1995, 33: 77-79.</li>
<a name="207"></a><li value="207">Antibacterial Products and Markets. Scrip Reports. 1997: 59-72.</li>
<a name="208"></a><li value="208">Janicki R.S., Garnham J.C., Worlaud M.C., et al. Comparison of erythromycin ethylsuccinate, stearate and estolat treatments of group A streptococcai infections of the upper respiratory tract. Clin. Pediatr., 1975, 14: 1098-1107.</li>
<a name="209"></a><li value="209">Ginsburgh C.M., McCracken J.G.U., Crow S.D., et al. Erythromycin therapy for group A streptococcal pharyngytis: results of comparative study of the estolate and ethylsuccinate formulations. Am. J.&nbsp;Dis. Child., 1984, 138; 536-539.</li>
<a name="210"></a><li value="210">Страчунский Л.С. Оптимизация антибактериальной терапии новорожденных детей. Автореф. докт. дисс. - М., 1993.</li>
<a name="211"></a><li value="211">Butler D., Kuhn R.J., Chandler M.H.H. Pharmacokinetics of anti-infective agents in paediatric patients. Clin. Pharmacokinet., 1994, 26: 374-395.</li>
<a name="212"></a><li value="212">Bryskier A., Butzler J.P. Macrolides. In: Antibiotic and chemotherapy: anti-infective agents and their use in therapy. O'Grady&nbsp;E., Lambert&nbsp;H.P., Finch&nbsp;R.G., Greenwood&nbsp;D. (Eds.). Churcill Livingstone. New York, etc., 1997: 377-393.</li>
<a name="213"></a><li value="213">Howard J.E., Nelson J.D., Clahsen J., et al. Otitis media of infancy and early childhood. Am. J. Dis. Child., 1976, 130: 965-970.</li>
<a name="214"></a><li value="214">Washington J.A. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (II). Mayo Clin. Proc., 1985, 60: 271-278.</li>
<a name="215"></a><li value="215">Disse В., Gundert-Remy U., Weber E., et al. Pharmacokinetics of erythromycin in patients with different degrees of renal impairment. Int. J.&nbsp;Clin. Pharmacol. Ther. Toxicol., 1986, 24: 460-464.</li>
<a name="216"></a><li value="216">Ellsworth A.J., Christensen D.B., Voipone-McMahon M.T. Prospective comparison of patient tolerance to enteric-coated vs. nonenteric-coated erythromycin. J.&nbsp;Fam. Pract., 1990, 31: 265-270.</li>
<a name="217"></a><li value="217">Tolman K.G., Sannella J.J., Freston J.W. Chemical structure of erythromycin and hepatotoxicity. Ann. Int. Med., 1974, 81: 58-60.</li>
<a name="218"></a><li value="218">Pessayre D., Larrey D., Funck-Brentano C., et al. Drug interactions and hepatitis produced by some macrolide antibiotics. J.&nbsp;Antimicrob. Chemother., 1985, 16 (suppl.&nbsp;A): 181-194.</li>
<a name="219"></a><li value="219">Ball A.P. Therapeutic considerations for the management of respiratory tract infection: the role of new macrolides and fluoroquinolones. Infec. Med., 1991, 8 (suppl.&nbsp;A): 7-17.</li>
<a name="220"></a><li value="220">Reese R.E., Betts R.F. Antibiotic use. In: A Practical Approach to Infectious Diseases. Reese R.E., Betts R.F. (Eds.). 3rd ed. Boston etc., 1991: 821-1007.</li>
<a name="221"></a><li value="221">Schonenberger R.A., Haefel W.E., Weiss P., et al. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes). Br. Med. J., 1990, 300: 1375-1376.</li>
<a name="222"></a><li value="222">Farrar H.C., Walsh-Sukys M.C., Kyllonen К., et al. Cardiac toxicity associated with inytravenous erythromycin lactobionate: two case reports and a review of the literature. Pediatr. Infect. Dis.&nbsp;J., 1993, 12: 688-691.</li>
<a name="223"></a><li value="223">Haefeli W.E., Schoenenberger R.A., Weiss P., et al. Possible risk for cardiac arrhythmia related to intravenous erythromycin. Intensive Care Med., 1992, 18: 469-473.</li>
<a name="224"></a><li value="224">Zhang Z.Q., Antzelevitch С. Erythromycin produces prominent action potential prolongation and early after depolarization-induced triggered activity in M but not epicardial and endocardial regions of the canine ventricle. Circulation, 1993, 88 (suppl.&nbsp;С): 1753.</li>
<a name="225"></a><li value="225">Haydon R.C., Thaelin J.W., Davis W.E. Erythromycin ototoxicity: Analysis and conclusions based on 22 case reports. Otolaryngol. Head Neck Surg., 1984, 92: 678-684.</li>
<a name="226"></a><li value="226">Swanson D.J., Sung R.J., Fine M.J., et al. Erythromycin ototoxicity: Prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am. J.&nbsp;Med., 1992, 92: 61-68.</li>
<a name="227"></a><li value="227">Disney F.A., Downton M.I., Higgins J.E., et al. Comparison of once-daily cefadroxil and four-times-daily erythromycin in Group A streptococcal pharyngitis. Adv. Ther., 1990, 7: 312-326.</li>
<a name="228"></a><li value="228">Milatovic D. Evaluation of cefadroxil, penicillin and erythromycin in the treatment of streptococcal tonsillopharyngitis. Pediatr. Infect. Dis., 1991, 10: 61-63.</li>
<a name="229"></a><li value="229">Lisby-Sutch S., Nemec-Dwyer M., Deeter R.G., et al. Therapy of otitis media. Clin, Pharm., 1990, 9: 15-34.</li>
<a name="230"></a><li value="230">Kirby B.D., Snyder K.M., Myer R.D., et al. Legionnairs' disease:
Report of sixty-five noaocomially acquired cases and review of the literature. Medicine, 1980, 59: 188-205.
</li>
<a name="231"></a><li value="231">Muder R.F., Yu V.L., Zuravleff M.S. Pneumonia due to the Pittsburgh pneumonia agent: New clinical perspective with a review of the literature. Medicine, 1983, 62: 120-128.</li>
<a name="232"></a><li value="232">Dournon E., Mayaud С., Wolff M., et al. Comparison of the activity of three antibiotic regimens in severe Legionnairs' disease. J.&nbsp;Antimicrob, Chemother., 1990, 26 (suppl.&nbsp;В): 129-139.</li>
<a name="233"></a><li value="233">Sprauer M.A., Cochi S.L., Zell E.R., et al. Prevention of secondary transmission of pertussis in households with early use of erythromycin. Am. J. Dis. Child., 1992, 146: 177-181.</li>
<a name="234"></a><li value="234">Atmar R.L., Greenberg S.В. Pneumonia caused by <i>Mycoplasma pneumoniae</i> and the TWAR agent. Semin. Resp. Infect., 1989, 4: 19-31.</li>
<a name="235"></a><li value="235">Grayston J.I. <i>Chlamydia pneumoniae</i> strain TWAR pneumonia. Ann. Rev. Med., 1992, 43: 317-323.</li>
<a name="236"></a><li value="236">Schlick W. The problems of treating atypical pneumonia. J.&nbsp;Antimicrob. Chemother., 1993, 31 (suppl.&nbsp;С): 111-120.</li>
<a name="237"></a><li value="237">Waites К.В., Sims P.J., Crouse D.T., et al. Serum concentrations of erythromycin after intravenous infusion in preterm neonates treated for <i>Ureaplasma urealyticum</i> infection. Pediatr. Infect. Dis.&nbsp;J., 1994, 13: 287-293.</li>
<a name="238"></a><li value="238">Eady E.A., Holland К.Т., Cunliff W.L. The use of antibiotics in acne therapy: oral or topical administration? J.&nbsp;Antimicrob, Chemother., 1982, 10: 89-115.</li>
<a name="239"></a><li value="239">Goldstein E.J.C. Bite wounds and infection. Clin. Infect. Dis., 1992, 14: 633-640.</li>
<a name="240"></a><li value="240">Anders B.J., Lauer B.A., Paisley J.W., et al. Double-blind placebo controlled trial of erythromycin for treatment of <i>Campylobacter</i> enteritis. Lancet, 1982, 1: 131-132.</li>
<a name="241"></a><li value="241">Berger T.G. Dermatologic care in the AIDS patient. In The Medical Management of AIDS. Sande&nbsp;M.A., Volberding&nbsp;P.A. (Eds.). Philadelphia, 1992: 151.</li>
<a name="242"></a><li value="242">Clarke J.S., Condon R.E., Fenton L.J., et al. Preoperative oral antibiotics reduce septic complications of colon operations; Results of prospective randomized, double-blind clinical study. Ann. Surg., 1977, 186: 251-259.</li>
<a name="243"></a><li value="243">Handbook of Antimicrobial Therapy. The Medical Letter on Drug
and Therapeutics. New Rochelle, NY: Medical Letter, 1992.</li>
<a name="244"></a><li value="244">Spector S.L., Katz F.H., Farr R.S. Troieandomycin; effectiveness in steroid-dependent asthma and bronchitis. J.&nbsp;Allergy Clin. Immunol, 1974, 6: 367-379.</li>
<a name="245"></a><li value="245">Paulsen 0. Roxithromycin - a macrolide with improved pharmacokinetic properties. Drugs Today, 1991, 27: 193-222.</li>
<a name="246"></a><li value="246">Kohno S., Hara K., Matsumoto F. A review of Japanese studies of roxithromycin. Pharmacokinetics, microbiology and clinical studies, particularly in the treatment of respiratory infection. Drug Invest., 1993, 5: 93-97.</li>
<a name="247"></a><li value="247">Rolston K.V., Ho D.V., LeBlanc B. Comparative <i>in&nbsp;vitro</i> activity of the new erythromycin derivative dirithromycin against Grampositive bacteria isolated from cancer patients. Eur. J.&nbsp;Clin. Microbiol, 1990, 9: 30-33.</li>
<a name="248"></a><li value="248">Tejada M., Malizia T., Marchetti F., et al. <i>In vitro</i> synergic interaction of roxithromycin with proton pump inhibitors and bismuth subcitrate against <i>Helicobacter pylori</i>. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996, Roxithromycin Posters: 14.</li>
<a name="249"></a><li value="249">Perez-Trallero E., Alcorta M., Montes M., et al. Comparative activity of macrolides against <i>H.pylori</i>. In: The 36th International Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996: abstr. E62.</li>
<a name="250"></a><li value="250">Samra Z., Rosenberg S., Kaufman L. Antibiotic susceptibility of <i>Ureaplasma urealyticum</i>. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 146.</li>
<a name="251"></a><li value="251">Samra Z., Rosenberg S., Luzon A. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 2.04.</li>
<a name="252"></a><li value="252">Bryskier A., Bretz A.G., Peter 0. Lyme disease - <i>in vitro</i> activity of the combination of roxithromycin and minocycline against the three subspecies of <i>B.burgdorferi</i>, In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 1.07.</li>
<a name="253"></a><li value="253">Rastogi N., Seng Gon K., Bryskier A. Activity of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin and clofazimine against the <i>Mycobacterium avium</i> complex. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: absrt. 299.</li>
<a name="254"></a><li value="254">Romand S., Derouin F. Synergism of roxithromycin and pyrimethamin or sulfadiazine against <i>Toxoplasma gondii</i>. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New York, etc., 1995: 334-340.</li>
<a name="255"></a><li value="255">Young R.A., Gonzalez J.P., Sorkin E.M. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs, 1989,37: 8-41.</li>
<a name="256"></a><li value="256">Rolin 0., Bouanchaud D.H. Comparison of <i>in&nbsp;vitro</i> post-antibiotic effect induced by 14-membered-ring macrolides (erythromycin and roxithromycin) and 16-membered-ring macrolides ( josamycin and spiramycin) in <i>Staphylococcus aureus</i>. Pathol. Biol., 1989, 37: 375-377.</li>
<a name="257"></a><li value="257">Moneib N.A., Shibl A.M., El-Said M.A., et al. Macrolides induced suppression of virulence factors produced by <i>Staphylocoocus aureus</i>. J.&nbsp;Chemother., 1993, 5: 289-292.</li>
<a name="258"></a><li value="258">Konno S., Asano K., Kurokawa M., et al. Antiasthmatic activity of a macrolide antibiotic: analysis of possible mechanisms <i>in&nbsp;vitro</i> and <i>in&nbsp;vivo</i>. Int. Arch. Allergy Appl. Immunol., 1994, 105: 308-316.</li>
<a name="259"></a><li value="259">Wongtim S., Charoenlap P., Limthongkul S., et al. Effect of roxithromycin on bronchial hyperresponsiveness in patients with cough variant asthma. In: The 20th International Congress of Chemotherapy. Sydney, 1997: abstr. 3028.</li>
<a name="260"></a><li value="260">Koyama M., Tateno M., Shirotsuka M., et al. Absorbtion, metabolism and excretion of RU 28965 in humans. Chemotherapy, 1988, 36 (suppl.&nbsp;4): 164-183.</li>
<a name="261"></a><li value="261">Saito A., Kato Y., Odagaki E., et al. Pharmacokinetics and clinical results of RU 28965. Chemotherapy, 1988, 36 (suppl.&nbsp;4): 216-223.</li>
<a name="262"></a><li value="262">Shiba K., Saito A., Shimada J., et al. Basic and clinical studies on RU 28965. Chemotherapy, 1988, 36 (suppl.&nbsp;4): 292.</li>
<a name="263"></a><li value="263">Begue P., Kafetzis D.A., Albin H., et al. Pharmacokinetics of roxithromycin in paediatrics. J.&nbsp;Antimicrob. Chemother., 1987, 20 (suppl.&nbsp;B): 101-106.</li>
<a name="264"></a><li value="264">Masaki M., Inoue Y., Mashimoto H., et al. Laboratory and clinical studies on RU 28965. Chemotherapy, 1988, 36 (suppl.&nbsp;4): 421-437.</li>
<a name="265"></a><li value="265">Hoffler D., Koeppe P., Sorgel F., et al. The parmacokinetics of roxithromycin in dialysis patient. In: The 18th International Congress of Chemotherapy. Stockholm, 1993: abstr. 260.</li>
<a name="266"></a><li value="266">Babany G., Roulot D., Chretien P., et al. Pharmacokinetics of
single and repeated oral doses of roxithromycin in patients with cirrhosis. In:
The 16th Congress of Chemotherapy. Jerusalem, 1989: abstr. 222.</li>
<a name="267"></a><li value="267">Wehrmann T., Rudolph U., Lembcke B., et al. Roxithromycin and
erythromycin exert different effects on postprandial antroduodenal motor function and gastrointestinal symptoms in healthy subjects. Eur. J.&nbsp;Gastroenterol. Hepatol., 1993, 5: 829-834.</li>
<a name="268"></a><li value="268">Esteban A., Molina M.J., Soto C. Acute cholestatic hepatitis due to roxithromycin. Rev. Clin. Esp., 1993, 192: 352-353.</li>
<a name="269"></a><li value="269">Pedersen F.M., Bathum L., Fenger C. Acute hepatitis and roxithromycin. Lancet, 1993, 341: 251-252.</li>
<a name="270"></a><li value="270">Pecquet S., Chachaty E., Tancrede C., et al. Effects of roxithromycin on fecal bacteria in human volunteers and resistance to colonization in gnotobiotic mice. Antimicrob. Agents Chemother., 1991, 35: 548-552.</li>
<a name="271"></a><li value="271">Niki Y., Soejima R. Roxithromycin does not affect electrocardiograms of healthy volunteers in the case of concomitant use with terfenadine. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.34.</li>
<a name="272"></a><li value="272">Nilsen 0. Roxithromycin does not change terfenadine pharmacokinetics or electrocardiology. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.33.</li>
<a name="273"></a><li value="273">Kees F., Ittner K.P., Mair G., et al. Kinetic synergism: omeprazole and roxithromycin. In: The 20th International Congress of Chemotherapy. Sydney, 1997: abstr. 4222.</li>
<a name="274"></a><li value="274">Pechere J.-C. Clinical evaluation of roxithromycin 300&nbsp;mg once daily as an alternative to 150&nbsp;mg twice daily. Diagn. Microbiol. Infect. Dis., 1992, 15 (suppl.&nbsp;4): 111S-117S.</li>
<a name="275"></a><li value="275">Lorenz J. Multicenter study on the efficacy and tolerance of roxithromycin in the treatment of respiratory tract Infections. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 413-417.</li>
<a name="276"></a><li value="276">Saldarriaga A. Roxithromycin, 150&nbsp;mg bid, for treatment of sinusitis. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 435-438.</li>
<a name="277"></a><li value="277">DeCampora E., Camaioni A., Leonardi M. Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections. Diagn. Microbiol. Infect. Dis., 1992, 15 (suppl.&nbsp;4): 119S-122S.</li>
<a name="278"></a><li value="278">Cooper B.C., Mullins P.R., Jones M.R., et al. Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to <i>Haemophilus influenzae</i>. A meta-analysis of 12 clinical studies. Drug Invest., 1994, 7: 299-314.</li>
<a name="279"></a><li value="279">Portier H. Overview of the efficacy and safety of roxithromycin
versus control antibiotics in the treatment of infections in adults. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 403-408.</li>
<a name="280"></a><li value="280">Bisetti A., Grassi L., Fiorucci F., et al. Open randomized comparison of activity and tolerance of roxithromycin vs clarithromycin in the treatment of lower respiratory tract infections. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 271.</li>
<a name="281"></a><li value="281">Stamboulian D., Perianu M. The efficacy of roxithromycin (300&nbsp;mg once daily or 150&nbsp;mg BID) in the treatment of &quot;atypical&quot; pneumonia in an international multicentre study. In: The 17th International Congress of Chemotherapy. Berlin, 1991.</li>
<a name="282"></a><li value="282">Antela A., Guerrero A., Escudero R., et al. Efficacy and safety of roxithromycin as empiric therapy for lower respiratory tract infections. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 278. </li>
<a name="283"></a><li value="283">Agache P., Amblard P., Moulin G., et al. Roxithromycin in skin and soft tissue infections. J.&nbsp;Antimicrob. Chemother., 1987, 20 (suppl.&nbsp;B): 153-156.</li>
<a name="284"></a><li value="284">Nohara N., Akagi M., Kanzaki H. Comparative double blind test of roxithromycin and josamycin on purulent diseases. Chemotherapy Tokyo, 1989, 37: 1518-1519.</li>
<a name="285"></a><li value="285">Bernard P., Plantin P., Roger H., et al. Roxithromycin versus penicillin in he treatment of erysipelas in adults: a comparative study. Br. J.&nbsp;Dermatol., 1992, 127: 155-159.</li>
<a name="286"></a><li value="286">Choroszy-Krol I., Ruczkowska J. Roxithromycin (Rulid) in the treatment of chlamidial urethritis in men. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 2.25.</li>
<a name="287"></a><li value="287">Negostani N., d&rsquo;Antuono A. Efficacy of roxithromycin vs minocycline in the treatment of non gonococcal urethritis: clinical and microbiological aspects. In: The 16th Congress of Chemotherapy. Jerusalem, 1989: abstr. 252.</li>
<a name="288"></a><li value="288">Narimatsu A., Ito T., Ono M., et al. Chlamidial infections in the fields of ginecology and obstetrics. In: The 18th International Congress of Chemotherapy. Stockholm, 1993: abstr. 283.</li>
<a name="289"></a><li value="289">Rosales M., Dominguez V., Bonacho I. Roxithromycin versus doxycycline in the treatment of cervicitis due to <i>Chlamidia trachomatis</i> in asymptomatic women. Rev. Clin. Esp., 1993, 192: 253-255.</li>
<a name="290"></a><li value="290">Bircher A.J., Gelzer D., Rufli T. Roxithromycin in the treatment of non-gonococcal urethritis. A double blind comparison of two treatment regimens. In: The 16th Congress of Chemotherapy. Jerusalem, 1989: abstr. 226.</li>
<a name="291"></a><li value="291">Hansen K., Hovmark A., Lebech A.-M., et al. Roxithromycin in Lyme borreliosis: discrepant results of an <i>in&nbsp;vitro</i> and <i>in&nbsp;vivo</i> animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm. Venerol., 1992, 72: 297-300.</li>
<a name="292"></a><li value="292">Gasser R., Wendelin I., Reisinger E., et al. Combined therapy with
roxithromycin and co-trimoxazole in Lyme disease. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 508-515.</li>
<a name="293"></a><li value="293">Uip D.E., Lima A.L.M., Amato V.S., et al. The use of roxithromycin in the diarrhea caused by <i>Cryptosporidium</i> spp. associated to AIDS. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 7.27.</li>
<a name="294"></a><li value="294">Okamoto S., Haruma K., Kawaguchi H., et al. Study on eradication of <i>Helicobacter pylori</i> by the combination use of roxithromycin, bismuth subnitrate, and omeprazole. In: The 18th International Congress of Chemotherapy. Stockholm, 1993: 282.</li>
<a name="295"></a><li value="295">Burette A., Glupczynski Y., Deprez C., et al. Lansoprazole plus roxithromycin and metronidazole for eradication of <i>Helicobacter pylori</i>: results of pilot study. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 520-523.</li>
<a name="296"></a><li value="296">Damann H.-G., Walter T.A. Roxithromycin, metronidazole and
roxatidine acetate triple therapy and <i>H.pylori</i> eradication rates. In: The 3rd
International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 5.24.</li>
<a name="297"></a><li value="297">Durant J., Hazime F., Bernard E., et al. An open randomized study of roxithromycin efficacy and tolerance in the primary prevention of pneumocystosis and cerebral toxoplasmosis in 52 HIV-patients. In: The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, 1991: abstr. 1216.</li>
<a name="298"></a><li value="298">Rahn R., Linde H.J., Riffel C., et al. Macrolides in prophylaxis for endocarditis. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 516-519.</li>
<a name="299"></a><li value="299">Kern W.V., Hay B., Kern P., et al. Efficacy of roxithromycin to prevent viridans streptococcal bacteriemia following cytotoxic chemotherapy. A randomized trial in patients with acute leukemia and bone marrow transplant patients receiving ofloxacin prophilaxis. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 314.</li>
<a name="300"></a><li value="300">Bazet M.C., Blanc F., Chumdermpadetsuk S., et al, Roxithromycin in the treatment of paediatric infections. Br. J.&nbsp;Clin. Pract., 1988, 42 (suppl.&nbsp;55): 117-118.</li>
<a name="301"></a><li value="301">Casellas J.M., Rodriguez H.A., Fernandez-Macloughlin G.J., et al. Efficacy of roxithromycin in the treatment of acute otitis media in infants. Br. J.&nbsp;Clin. Pract., 1988, 42 (suppl.&nbsp;55): 113-114.</li>
<a name="302"></a><li value="302">Stamboulian D., Fernandez-Macloughlin G.J., Lanoel J.L., et al, Clinical evaluation of roxithromycin in 101 children. Br. J.&nbsp;Clin. Pract., 1988, 42 (suppl.&nbsp;55): 115-116.</li>
<a name="303"></a><li value="303">Salvarezza C., Villar E., Ballario M. Estudio comparativo de la eficacia y tolerancia clinica de roxitromicina vs. amoxicillina en neumopatia extrahospitalarias en pediatria. Prensa Med. Argent., 1989, 76: 127-130.</li>
<a name="304"></a><li value="304">Guggenbichler J.P. First results of a new formulation of roxithromycin: a randomized controlled study in lower respiratory tract infections in infants and children. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 13.24.</li>
<a name="305"></a><li value="305">Laurencena E., Forti M.J. Roxithromycin in the treatment of acute otitis media in children. Prensa Med. Argent., 1992, 79: 577-579.</li>
<a name="306"></a><li value="306">Haentjes M., Levy J., De Boeck M., et al. Early treatment with roxithromycin of campylobacter associated enteritis in children. In: The 16th Congress of Chemotherapy. Jerusalem, 1989.</li>
<a name="307"></a><li value="307">Hardy D.J., Swanson R.N., Rode R.A., et al. Enhancement of the <i>in&nbsp;vitro</i> and <i>in&nbsp;vivo</i> activities of clarithromycin against <i>Haemophilus influenzae</i> by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob. Agents Chemother., 1990, 34: 1407-1413.</li>
<a name="308"></a><li value="308">Vallee E., Azoulay-Dupuis E., Swanson R., et al. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of <i>Haemophilus influenzae</i> infection. J.&nbsp;Antimicrob. Chemother., 1991, 27 (suppl.&nbsp;A): 31-41.</li>
<a name="309"></a><li value="309">Fraschini F., Scaglione F., Demartini G. Clarithromycin clinical pharmacokinetics. Clin. Pharmacokinet., 1993, 25: 189-204.</li>
<a name="310"></a><li value="310">Hardy D.J. Extent and spectrum of the antimicrobial activity of clarithromycin, Pediatr. Infect. Dis. J., 1993, 12: 99-105.</li>
<a name="311"></a><li value="311">Peters D.H., Clissold S.P. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs, 1992, 44: 117-164.</li>
<a name="312"></a><li value="312">Lemmen S.W., Anding K., Engels I., et al. Bactericidal activity of clarithromycin and cefaclor against <i>Streptococcus pneumoniae</i> and <i>Moraxella catarrhalis</i> in healthy volunteers. J.&nbsp;Antimicrob. Chemother., 1994, 33: 763-674.</li>
<a name="313"></a><li value="313">Scaglione F., Demartini G., Fraschini F. Distribution of clarithromycin to intracellular and extracellular sites of infection: an overview. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 380-385.</li>
<a name="314"></a><li value="314">Chin N.-X., Neu N.M., Labthavikul P., et al. Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother., 1987, 31: 463-466.</li>
<a name="315"></a><li value="315">Dubois J., Saint-Pierre С. <i>An in&nbsp;vitro</i> susceptibility study of clarithromycin against <i>Haemophilus, Streptococcus, Moraxella</i> and other strains isolated from maxillary sinus aspiration. In: The 20th International Congress of Chemotherapy. Sydney, 1997: abstr. 3031.</li>
<a name="316"></a><li value="316">Shortridge D., Beyer J., Flamm R.K., et al. Comparative <i>in&nbsp;vitro</i> activity of clarithromycin, azithromycin and other agents against clinical isolates of <i>Helicobacter pylori</i>. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 5.10.</li>
<a name="317"></a><li value="317">Yamaji Е., Nakayama I., Yoshikawa E. <i>In&nbsp;vitro</i> antibacterial activity of amoxicillin, clarithromycin, metronidazole, and tinidazole against <i>Helicobacter pylori</i>. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. E-21.</li>
<a name="318"></a><li value="318">Ives Т.Е., Regenery R.L., Manzewitsch P., et al. <i>In&nbsp;vitro</i> evaluation, of macrolide antibiotics against Bartonella (Rochalimaea) henselae B.quintana and B.clizabethae via immunofluorescent antibody testing. In; The 3rd International Conference on the Macrolides, Azalides and Siroptogramins. Lisbon, 1996: abstr. 8.10.</li>
<a name="319"></a><li value="319">Keren G., Rubinstein E., Keysary A., et al. Evaluation of antirickettsial activity of azithromycin and clarithroinycin in <i>in&nbsp;vitro</i> systems. In:
New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu&nbsp;H.C., Young&nbsp;L.S., Zinner&nbsp;S.H., Acar&nbsp;J.F. (Eds.). New&nbsp;York, etc., 1995: 291-296.</li>
<a name="320"></a><li value="320">Kohno S., Koga H., Yamaguchi K., et al. A new macrolide, TE-031 (A-56268), in treatment of experimental Legionnairs&rsquo; disease. J.&nbsp;Antimicrob. Chemother., 1989, 24: 397-405.</li>
</ol>

<br>
<!--counters-->
<table border="0" cellpadding="0" cellspacing="5" width="100%">
<tr>
  <td align="left" valign="bottom" style="vertical-align:bottom;"><font class="t8">&copy; 2000-2007 <a target="_blank" href="../../copyright.php.html">НИИАХ СГМА</a></font></td>
  <td align="right">
<!--Rambler 1x1--><a href="http://top100.rambler.ru/top100/"><img src="../../top100.cnt.gif?335834" alt="Rambler's Top100" width="1" height="1" border="0"></a><!--/Rambler 1x1-->

<!--TopList--><a target="_top" href="http://top.list.ru/jump?from=96637"><img src="../../counter-1.gif?id=96637;t=58" border="0" height="31" width="88" alt="TopList"></a><!--/TopList-->

<!--Rambler--><a href="http://top100.rambler.ru/top100/" target="_blank"><img src="../../top100/banner-88x31-rambler-darkblue2.gif" alt="Rambler's Top100" width="88" height="31" border="0"></a><!--/Rambler-->

<br><!--RAX--><script language="JavaScript"><!--
document.write('<a href="http://www.rax.ru/click" '+
'target=_blank><img src="http://counter.yadro.ru/hit?t26.11;r'+
escape(document.referrer)+((typeof(screen)=='undefined')?'':
';s'+screen.width+'*'+screen.height+'*'+(screen.colorDepth?
screen.colorDepth:screen.pixelDepth))+';'+Math.random()+
'" alt="rax.ru: показано число посетителей за сегодн\я" '+
'border=0 width=88 height=15></a>')//--></script><!--/RAX-->
  </td>
</tr>
</table>
<!--/counters-->

</body>
</html>
